Following the FDA ODAC's vote against belantamab mafodotin-based combinations in relapsed/refractory multiple myeloma, George Mulligan, PhD, provides insight into the agent's potential path foward.

There's an unmet need for effective treatments in PTSD, as current options include psychotherapy and the SSRIs sertraline and paroxetine (Paxil). These options carry various adverse effects, and the ...

Overview of Nanotechnology Drug Delivery MarketThe global Nanotechnology Drug Delivery Market is valued at USD 97.98 Billion ...

Peter Mac researchers have discovered a powerful new drug combination that could offer hope to children and adults with ...

Which drug combinations are best for prevention of nausea and vomiting caused by chemotherapy in adults with cancer?

MIT researchers have developed a new theoretical framework for studying the mechanisms of treatment interactions. Their ...

ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.

Verastem's FDA approval for KRAS-mutant LGSOC, strong pipeline, and catalysts signal growth potential. Click here to read an ...

STOCKHOLM, SE / ACCESS Newswire / July 15, 2025 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases ...

Novartis AG NVS, a Swiss pharma giant, is scheduled to report second-quarter 2025 results on July 17. The Zacks Consensus Estimate for revenues is pegged at $14.04 billion, while the same for earnings ...

Lantern Pharma Inc. (NASDAQ: LTRN), a pioneering artificial intelligence (AI) company transforming oncology drug discovery ...